SCHEDULE: Hudson Bay Capital Discloses 5.22% Stake in SpringWorks

Hudson Bay Capital Management LP and Sander Gerber have disclosed a 5.22% beneficial ownership stake in SpringWorks Therapeutics, Inc., including shares from call options.

Summary

• Hudson Bay Capital Management LP and Sander Gerber collectively reported beneficial ownership of 3,936,857 shares of SpringWorks Therapeutics, Inc. Common Stock.
• This ownership represents 5.22% of the company's outstanding Common Stock.
• The reported shares include 3,529,200 shares of Common Stock issuable upon the exercise of call options.
• The percentage of class is calculated based on 75,348,995 shares of Common Stock outstanding as of May 27, 2025, as reported in the company's Definitive Proxy Statement on Schedule 14A.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant beneficial ownership stake by a reputable investment firm like Hudson Bay Capital Management LP can be viewed as a positive signal of institutional interest and confidence in SpringWorks Therapeutics, Inc.

Positives

• The disclosure of a significant beneficial ownership stake by Hudson Bay Capital Management LP, a reputable investment firm, may signal institutional confidence in SpringWorks Therapeutics, Inc.

Risks

• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating potential control-related risks from this specific stake.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the company.

Industry Context

This filing represents a standard disclosure of a significant passive investment by an institutional investor in a publicly traded biotechnology company. It reflects an investment decision by Hudson Bay Capital Management LP in SpringWorks Therapeutics, Inc., rather than a broader industry trend or competitive action.

Stakeholder Impact

• Shareholders may perceive this significant institutional investment as a vote of confidence in the company's prospects, potentially influencing investor sentiment.

Key Dates

Recommendation

The filing indicates a significant beneficial ownership stake by Hudson Bay Capital Management LP, a notable investment firm. While this suggests institutional confidence, a Schedule 13G is a disclosure of ownership, not a financial performance report or strategic update. Investors should consider this information as a data point indicating institutional interest but should conduct further due diligence on SpringWorks Therapeutics' fundamentals, pipeline, and market position before making investment decisions.

Keywords

SpringWorks Therapeutics, Hudson Bay Capital Management, Sander Gerber, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investment, Common Stock, Biotechnology, Pharmaceutical